Autoimmune hepatitis

Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671-722.全文  摘要

European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015 Oct;63(4):971-1004. 摘要

Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec;60(12):1611-29.全文  摘要

Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug;29(3):273-85. 摘要

Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012 Oct;36(8):691-707.全文  摘要

1. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671-722.全文  摘要

2. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004 Oct 15;1(1):2.全文  摘要

3. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54-66. 摘要

4. Lv T, Li M, Zeng N, et al. Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population. J Gastroenterol Hepatol. 2019 Oct;34(10):1676-84. 摘要

5. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014 Mar;60(3):612-7. 摘要

6. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010 Oct;25(10):1681-6. 摘要

7. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014 Oct;49(10):1245-54. 摘要

8. Radhakrishnan KR, Alkhouri N, Worley S, et al. Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010 Oct;42(10):724-8. 摘要

9. Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013 Oct;58(4):1392-400.全文  摘要

10. Jiménez-Rivera C, Ling SC, Ahmed N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics. 2015 Nov;136(5):e1237-48. 摘要

11. Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut. 2021 Oct;70(10):1989-2003. 摘要

12. Moy L, Levine J. Autoimmune hepatitis: a classic autoimmune liver disease. Curr Probl Pediatr Adolesc Health Care. 2014 Dec;44(11):341-6. 摘要

13. Czaja AJ. Autoimmune hepatitis: approach to diagnosis. MedGenMed. 2006 May 23;8(2):55.全文  摘要

14. Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers. 2018 Apr 12;4:18017. 摘要

15. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2006 May;22(3):234-40. 摘要

16. Jenkins A, Austin A, Hughes K, et al. Infliximab-induced autoimmune hepatitis. BMJ Case Rep. 2021 May 24;14(5):e239944. 摘要

17. Franco DL, Kale S, Lam-Himlin DM, et al. Black cohosh hepatotoxicity with autoimmune hepatitis presentation. Case Rep Gastroenterol. 2017 Jan-Apr;11(1):23-8.全文  摘要

18. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006 Feb;43(2 Suppl 1):S132-44. 摘要

19. Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and molecular mechanisms of autoimmune hepatitis. Annu Rev Pathol. 2018 Jan 24;13:247-92.全文  摘要

20. Wang Q, Yang F, Miao Q, et al. The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J Autoimmun. 2016 Jan;66:98-107. 摘要

21. Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J Gastroenterol. 2011 Apr 28;17(16):2070-5.全文  摘要

22. Braga AC, Vasconcelos C, Braga J. Pregnancy with autoimmune hepatitis. Gastroenterol Hepatol Bed Bench. 2016 Summer;9(3):220-4.全文  摘要

23. Al-Chalabi T, Underhill JA, Portmann BC, et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1389-95.全文  摘要

24. Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol. 2021 Jan;27(1):58-69.全文  摘要

25. Yang F, Wang Q, Bian Z, et al. Autoimmune hepatitis: east meets west. J Gastroenterol Hepatol. 2015 Aug;30(8):1230-6.全文  摘要

26. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015 Oct;63(4):971-1004. 摘要

27. Sebode M, Weiler-Normann C, Liwinski T, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018 Mar 27;9:609.全文  摘要

28. Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol. 2010 Apr;24(4):225-31.全文  摘要

29. Manns MP. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol. 2000 Aug;33(2):326-8.全文  摘要

30. Expert Panel on Gastrointestinal Imaging, Arif-Tiwari H, Porter KK, et al. ACR appropriateness criteria® abnormal liver function tests. J Am Coll Radiol. 2023 Nov;20(11s):S302-14.全文  摘要

31. Dong Y, Potthoff A, Klinger C, et al. Ultrasound findings in autoimmune hepatitis. World J Gastroenterol. 2018 Apr 21;24(15):1583-90.全文  摘要

32. Sue MJ, Lee EW, Saab S, et al. Transjugular liver biopsy: safe even in patients with severe coagulopathies and multiple biopsies. Clin Transl Gastroenterol. 2019 Jul;10(7):e00063.全文  摘要

33. Thomaides-Brears HB, Alkhouri N, Allende D, et al. Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis. Dig Dis Sci. 2022 Jul;67(7):3366-94.全文  摘要

34. Tiniakos DG, Brain JG, Bury YA. Role of histopathology in autoimmune hepatitis. Dig Dis. 2015;33 Suppl 2:53-64.全文  摘要

35. Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec;60(12):1611-29.全文  摘要

36. Welz-Kubiak K, Reszke R, Szepietowski JC. Pruritus as a sign of systemic disease. Clin Dermatol. 2019 Nov-Dec;37(6):644-56. 摘要

37. European Association for the Study of the Liver; Clinical Practice Guideline Panel; Chair, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-89.全文  摘要

38. Tonolini M, Bianco R. HIV-related/AIDS cholangiopathy: pictorial review with emphasis on MRCP findings and differential diagnosis. Clin Imaging. 2013 Mar-Apr;37(2):219-26. 摘要

39. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929-38. 摘要

40. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169-76.全文  摘要

41. American College of Radiology. ACR appropriateness criteria®: abnormal liver function tests. 2023 [internet publication].全文

42. Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010 Jul;53(1):191-8.全文  摘要

43. Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther. 2010 Apr;31(8):771-87.全文  摘要

44. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008 Apr;22(4):388-92.全文  摘要

45. Wiegand J, Schüler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005 Oct;25(5):927-34. 摘要

46. Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug;29(3):273-85. 摘要

47. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010 Oct;139(4):1198-206. 摘要

48. Csepregi A, Röcken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006 Mar 7;12(9):1362-6. 摘要

49. Woynarowski M, Nemeth A, Baruch Y, et al; European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013 Nov;163(5):1347-53.e1. 摘要

50. Yu ZJ, Zhang LL, Huang TT, et al. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):873-7. 摘要

51. Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012 Oct;36(8):691-707.全文  摘要

52. Nasseri-Moghaddam S, Nikfam S, Karimian S, et al. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. Middle East J Dig Dis. 2013 Oct;5(4):193-200.全文  摘要

53. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001 Jun;46(6):1321-7. 摘要

54. Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol. 2014 Jan;60(1):210-23.全文  摘要

55. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002 Jun;8(6):519-26.全文  摘要

56. Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014 Nov;127(11):1128-31. 摘要

57. D'Agostino D, Costaguta A, Álvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013 Aug;132(2):e526-30. 摘要

58. Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013 Mar;58(3):529-34. 摘要

59. Wong F, Al Ibrahim B, Walsh J, et al. Infliximab-induced autoimmune hepatitis requiring liver transplantation. Clin Case Rep. 2019 Sep 27;7(11):2135-9.全文  摘要

60. Karanfilian B, Mahpour N, Sarkar A. Infliximab drug-induced autoimmune hepatitis in a patient with Crohn's ileocolitis. Am J Ther. 2020 Dec 29 [Epub ahead of print]. 摘要

61. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology. 1999 Dec;30(6):1381-6. 摘要

62. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002 Feb;35(2):409-13.全文  摘要

63. Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Hepatology. 2014 Jul;60(1):362-98.全文  摘要

64. Abhyankar A, Tapper E, Bonder A. Immunosuppressive therapy in immune-mediated liver disease in the non-transplanted patient. Pharmaceuticals (Basel). 2013 Dec 30;7(1):18-28.全文  摘要

65. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011 Jun;140(7):1980-9.全文  摘要

66. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009 Jul;51(1):161-7. 摘要

67. Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019 Nov 25;2019:9437043.全文  摘要

68. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009 Aug;29(3):315-30. 摘要

69. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006 Mar;43(3):532-8.全文  摘要

70. Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006 Oct;36(2):139-42. 摘要

71. Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007 Oct;13(10):1382-8.全文  摘要

72. Al-Chalabi T, Underhill JA, Portmann BC, et al. Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol. 2008 Jan;48(1):140-7. 摘要

73. Sharma R, Simon TG, Stephansson O, et al. Pregnancy outcomes in women with autoimmune hepatitis - a nationwide population-based cohort study with histopathology. Clin Gastroenterol Hepatol. 2023 Jan;21(1):103-14.e10.全文  摘要

74. Westbrook RH, Yeoman AD, Kriese S, et al. Outcomes of pregnancy in women with autoimmune hepatitis. J Autoimmun. 2012 May;38(2-3):J239-44. 摘要

75. Bozward AG, Wootton GE, Podstawka O, et al. Autoimmune hepatitis: tolerogenic immunological state during pregnancy and immune escape in post-partum. Front Immunol. 2020 Sep 24;11:591380.全文  摘要

76. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003 Jan;124(1):9-17.全文  摘要

77. Natekar A, Pupco A, Bozzo P, et al. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011 Dec;57(12):1401-2.全文  摘要

78. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan;19(1):15-22. 摘要

79. Mendizabal M, Marciano S, Videla MG, et al. Fulminant presentation of autoimmune hepatitis: clinical features and early predictors of corticosteroid treatment failure. Eur J Gastroenterol Hepatol. 2015 Jun;27(6):644-8. 摘要

80. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007 Oct;46(4):1138-45. 摘要

81. Schramm C, Wahl I, Weiler-Normann C, et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol. 2014 Mar;60(3):618-24. 摘要

82. UK Health Security Agency. Hepatitis A: the green book, chapter 17. Jan 2024 [internet publication].全文